WO1998030615A1 - Polymers - Google Patents
Polymers Download PDFInfo
- Publication number
- WO1998030615A1 WO1998030615A1 PCT/GB1998/000070 GB9800070W WO9830615A1 WO 1998030615 A1 WO1998030615 A1 WO 1998030615A1 GB 9800070 W GB9800070 W GB 9800070W WO 9830615 A1 WO9830615 A1 WO 9830615A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- groups
- hydrogen
- alkyl
- oxaalkylene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F230/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
- C08F230/04—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal
- C08F230/08—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon
- C08F230/085—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon the monomer being a polymerisable silane, e.g. (meth)acryloyloxy trialkoxy silanes or vinyl trialkoxysilanes
Definitions
- HMJ03002GB POLYMERS This invention relates to new polymeric materials especially suitable for use in biomedical applications, and processes for their production and use.
- a crosslinkable polymer formed from monomers including a) a hydroxyl-group containing monomer of the general formula I R 26 O
- R b is hydrogen or C 1 . 4 -alkyl group
- a 1 is -O- or - NR 27 - where R 27 is hydrogen or a C 1 . 4 - alkyl group or a group
- B 9 is a bond, a straight or branched alkylene, a oxa alkylene or oligooxa alkylene group;
- R 13 is a n + l functional (optionally substituted) C 4 alkylene group, n is an integer of one or more; and b) a reactive monomer of the general formula (II)
- R 19 is hydrogen or a C 1 . 4 -alkyl group or A 2 is -O- or -NR 21 - where R 21 is hydrogen, or a C ⁇ -alkyl group
- R 12 is Cj. 24 straight or branched alkylene, oxaalkylene or oligo oxaalkylene group in which each alkylene group has 1 to 6 carbon atoms
- a 3 is a band or -O- each R 16 independently selected from Cj.g-alkyl groups.
- R 2b is preferably hydrogen or methyl, most preferably methyl.
- a 1 is preferably -O-.
- B 9 is preferably a bond.
- R 13 is preferably selected from C 2 _ 6 -alkylene groups, most preferably C 2 . 4 -alkylene, most preferably propylene.
- the monomer I may consist of a mixture of compounds having different groups R 13 .
- all groups R 13 have the same number of carbon atoms, but may comprise a mixture of different isomers.
- the group R 13 is propylene, it may consist of a mixture of 1, 2-propylene and 1, 3-propylene.
- R 19 is preferably selected from hydrogen and methyl groups, most preferably R 19 is methyl.
- a 2 is preferably -0-.
- a 3 is preferably -0-.
- R 12 is preferably C 2 _ 6 -alkylene, preferably C 2 _ 4 -alkylene.
- the monomer of the formula II may comprise a mixture of compounds having different groups R 12 .
- R lb is selected from C ⁇ -alkyl groups, preferably C h alky1 groups.
- Preferred polymers are made from monomers including a zwitterionic monomer of the general formula III
- B is a straight or branched alkylene, oxaalkylene or oligo-oxaalkylene chain optionally containing one or more fluorine atoms up to and including perfluorinated chains or, if X contains a carbon-carbon chain between B and the zwitterionic moiety or if Y contains a terminal carbon atom bonded to B, a valence bond; X is a zwitterionic group R is hydrogen or a C ⁇ -C 4 alkyl group; and A is -O- or -NR 1 - where R 1 is hydrogen or a C_-C 4 alkyl group or R 1 is -B-X where B and X are as defined above.
- K and B contain up to 12 carbon atoms in total.
- R is preferably selected from hydrogen and methyl, and is most preferably methyl.
- B 9 is an alkylene group of formula -(CR 2 ) a - , wherein the groups -(CR 3 ,)- are the same or different, and in each group -(CR 3 2 )- the groups R 3 are the same or different and each group R 3 is hydrogen, fluorine or C ⁇ alkyl or fluoroalkyl, preferably hydrogen, and a is from 1 to 12, preferably 1 to 6; an oxaalkylene group such as alkoxyalkyl having 1 to 6 carbon atoms in each alkyl moiety, more preferably -CH 2 0(CH 2 ) 4 -; or an oligo-oxaalkylene group of formula -[ (CR 4 2 ) b O] c (CR 4 2 ) b - where the groups -(CR 2 )- are the same or different and in each group -(CR 2 )- the groups R 4 are the same or different and each group R 4 is hydrogen, fluorine or C 1 alkyl
- Preferred groups B include alkylene, oxaalkylene and oligo-oxaalkylene groups of up to 12 carbon atoms optionally containing one or more fluorine atoms.
- Preferred zwitterionic groups on zwitterionic monomer III are groups in which the cationic moiety is based on a quaternary ammonium group and the anionic moiety is based on a phosphate group.
- Preferred zwitterionic groups are ammonium phosphate ester zwitterionic groups.
- the ammonium is quaternary ammonium and the phosphate group is a diester group, or amide analogue.
- the cationic group is located at the end of pendant group X distant from B.
- X is a group of formula
- the moieties X 1 and X 2 which are the same or different, are -0-, -S-, -NH- or a valence bond, preferably -0-, and W + is a group comprising an ammonium, phosphonium or sulphonium cationic group and a group linking the anionic and cationic moieties which is preferably a C l . - alkylene group.
- the group + may for example be a group of formula - 1 -N + R 23 3 , -w'-P + R 23 ⁇ , -W'-S'R 23 ⁇ or -W ⁇ Het" in which: 1 is alkylene of 1 or more, preferably 2-6 carbon atoms optionally containing one or more ethylenically unsaturated double or triple bonds, disubstituted-aryl, alkylene aryl, aryl alkylene, or alkylene aryl alkylene, disubstituted cycloalkyl, alkylene cycloalkyl, cycloalkyl alkylene or alkylene cycloalkyl alkylene, which group W 1 optionally contains one or more fluorine substituents and/or one or more functional groups; and either the groups R 23 are the same or different and each is hydrogen or alkyl of
- Het is an aromatic nitrogen-, phosphorus- or sulphur-, preferably nitrogen-, containing ring, for example pyridine.
- W 1 is a straight-chain alkylene group, most preferably 1, 2-ethylene.
- R 6 are the same or different and each is hydrogen or C ⁇ ,, alkyl and d is from 2 to 4.
- the groups R 6 are the same. It is also preferable that at least one of the groups R b is methyl, and more preferable that the groups R 6 are both methyl.
- d is 2 or 3, more preferably 3.
- B is a group of formula -(CR 3 2 )- or -(CR 3 2 ) 2 -, eg. -(CH 2 )- or -(CH 2 CH 2 )-.
- the groups R 7 are the same. It is also preferable that at least one of the groups R 7 is methyl, and more preferable that the groups R 7 are all methyl.
- e is 2 or 3 , more preferably 2.
- X is a group of formula (IVB)
- B is a group of formula -(CR 3 2 )- or -(CR 3 2 ) 2 -, eg. -(CH 2 )- or -(CH 2 CH 2 )-.
- R 8a is hydrogen or, more preferably, a group -CfOJB ⁇ 80 where R 8b is hydrogen or methyl.
- B 1 is a valence bond or straight or branched alkylene, oxaalkylene or oligo-oxaalkalyene group, and f is from 1 to 4 ; and if B is other than a valence bond Z is 1 and if B is a valence bond Z is O, if X is directly bonded to an oxygen or nitrogen atom and otherwise Z is 1.
- the groups R 8 are the same. It is also preferable that at least one of the groups R 3 is methyl, and more preferable that the groups R 8 are all methyl.
- f is 1 or 2 , more preferably 2.
- B 1 is: a valence bond; an alkylene group of formula ⁇ (CR 3a 2 ) aa -, wherein the groups -(CR 3a 2 )- are the same or different, and in each group -(CR d 2 )- the groups R 3a are the same or different and each group R 3a is hydrogen or C ⁇ alkyl, preferably hydrogen, and is from 1 to 12, preferably 1 to 6; an oxaalkylene group such as alkoxyalkyl having 1 to 6 carbon atoms in each alkyl moiety, more preferably -CH 2 0(CH 2 ) 4 -; or an oligo-oxaalkylene group of formula -[ (CR a 2 ) ba O] ca - where the groups -(CR a 2 )- are the same or different and in each group -(CR a 2 )- the groups R a are the same or different and each group R is hydrogen or C, -4 alkyl, preferably hydrogen, and
- Preferred groups B 1 include a valence bond and alkylene, oxaalkylene and oligo-oxaalkylene groups of up to 12 carbon atoms.
- B and B 1 are the same.
- B is a group of formula -[ (CR 4 2 CR 4 2 ) c O b ]CR 4 2 CR 2 -, eg. -(CH 2 CH 2 0) c (CH 2 CH 2 )-.
- the groups of formula ( IVD) are :
- R 9 are the same or different and each is hydrogen or Cj-C 4 alkyl
- R 9a is a hydrogen or, more preferably, a group -C(0)B 2 R 9b
- R 9b is hydrogen or methyl, preferably methyl
- B 2 is a valence bond or a straight or branched alkylene, oxaalkylene or oligo-oxaalkylene group, and g is from 1 to 4; and if B is other than a valence bond Z is 1 and if B is a valence bond Z is 0 if X is directly bonded to an oxygen or nitrogen atom and otherwise Z is 1.
- the groups R 9 are the same. It is also preferable that at least one of the groups R 9 is methyl, and more preferable that the groups R 9 are all methyl.
- g is 1 or 2 , more preferably 2.
- B 2 is: a valence bond; an alkylene group of formula -(CR 3b 2 ) ab -, wherein the groups -(CR 3b 2 )- are the same or different, and in each group -(CR 3b 2 )- the groups R 3b are the same of different and each group R 3b is hydrogen or C ⁇ alkyl, preferably hydrogen, and ab is from 1 to 12, preferably 1 to 6; an oxaalkylene group such as alkoxyalkyl having 1 to
- each alkyl moiety more preferably -CH 2 0(CH 2 ) 4 -; or an oligo-oxaalkylene group of formula -[ (CR 4 2 ) bb O] cb - where the groups -(CR 4b 2 )- are the same or different and in each group -(CR 4b 2 )- the groups R b are the same or different and each group R is hydrogen or d- 4 alkyl, preferably hydrogen, and bb is from 1 to 6, preferably 2 or 3 , and cb is from 1 to 12 , preferably 1 to 6.
- Preferred groups B 2 include a valence bond and alkylene, oxalkylene and oligo-oxalkylene groups of up to 12 carbon atoms.
- B and B 2 are the same.
- X is a group of formula (IVD)
- B is a group of formula -[ (CR 4 2 CR 4 2 ) b O] c CR 4 2 CR 4 2 -, eg. -(CH 2 CH 2 0) c CH 2 CH 2 -.
- R 10 are the same or different and each is hydrogen or C,. 4 alkyl
- R 10a is hydrogen or, more preferably, a group -C(O)B 3 R 10b
- R 10b is hydrogen or methyl, preferably methyl
- B 3 is a valence bond or a straight or branched alkylene, oxaalkylene or oligo- oxaalkylene group, and h is from 1 to 4
- B is other than a valence bond Z is 1 and if B is a valence bond Z is O if X is directly bonded to the oxygen or nitrogen and otherwise Z is 1.
- the groups R 10 are the same. It is also preferable that at least one of the groups R 10 is methyl, and more preferable that the groups R 10 are all methyl.
- h is 1 or 2, more preferably 2.
- B 3 is: a valence bond; an alkylene group of formula -(CR 3c 2 ) ac -, wherein the groups -(CR 3c 2 )- are the same or different, and in each group -(CR 3c 2 )- the groups R 3c are the same or different and each group R 3c is hydrogen or C ⁇ .
- alkyl preferably hydrogen, and ac is from 1 to 12, preferably 1 to 6; an oxaalkylene group such as alkoxyalkyl having 1 to 6 carbon atoms in each alkyl moiety, more preferably -CH 2 0(CH 2 ) 4 -; or an oligo-oxaalkylene group of formula -[ (CR 4c 2 ) bc O] cc - where the groups -(CR c 2 )- are the same or different and in each group -(CR 4c 2 )- the groups R 4c are the same or different and each group R is hydrogen or C 1-4 alkyl, preferably hydrogen, and be is from 1 to 6, preferably 2 or 3 , and cc is from 1 to 12 , preferably 1 to 6.
- Preferred groups B 3 include a valence bond and alkylene, oxaalkylene and oligo-oxaalkylene groups of up to 12 carbon atoms. Preferably B and B 3 are the same.
- B is a group of formula -[ (CR 2 CR 2 ) b O] c CR 4 2 CR 2 -, eg. -(CH 2 CH 2 0) c CH 2 CH 2 -.
- a polymer according to the invention is preferably formed from monomers including a comonomer of the formula V
- R 14 is hydrogen or a C, - -a
- a 4 is ⁇ -0- or -NR 15 - where R 1 5 is hydrogen, C 1 . 4 -alkyl group or a group Q, and Q is selected from hydroxyl groups a straight or branched alkyl, alkoxyalkyl or (oligo- alkoxy) alkyl chain containing 1 to 24 carbon atoms unsubstituted or substituted by one or more fluorine atoms and optionally containing one or more carbon-carbon double or triple bonds; a siloxane group -(CR 16a 2 ) qq (SiR 16b 2 ) (OSiR l ⁇ b 2 ) pp R l ⁇ b in which each group R lba is the same or different and is hydrogen or alkyl of 1 to 4 carbon atoms or aralkyl, for example benzyl or phenethyl, each group R lbb is alkyl of 1 to 4 carbon atoms, qq is from 1 to 6 and pp is from 0 to
- C ! _ 24 -alkyl groups substituted with a group Q 5 selected from anionic groups selected from carboxylate, sulphonate, hydrogenphosphate and phosphate groups and cationic groups selected from -NR 31 3 in which each group R 31 3 in which each group R 31 is the same or different, and is hydrogen or alkyl of 1 to 6 carbon atoms two of which groups R 31 may together from a heterocyclic ring containing from 5 to 7 atoms, + N Het where Het is an unsaturated heterocyclic group substituted or unsubstituted by one or more alkyl groups of 1 to 4 carbon atoms, and groups P + R 32 3 in which each group R 32 is the same or different and is hydrogen or alkyl of 1 to 6 carbons atoms, two of which groups R 32 may together form a heterocyclic ring containing from 5 to 7 atoms.
- group Q 5 selected from anionic groups selected from carboxylate, sulphonate, hydrogenphosphate and phosphate groups and cationic
- group R 14 is preferably selected from hydrogen and methyl.
- a 4 is preferably -0-.
- the group Q is most conveniently a hydrophobic group, preferably an alkyl, a fluoroalkyl or a siloxane group.
- Preferred monomers V are comonomers in which Q is a) an alkyl group which group optionally contains one or more etheric oxygen atoms and optionally one or more carbon-carbon double or triple bonds for instance which has 6 or more carbon atoms, or b) a fluoroalkyl group, preferably of 6 or more carbon atoms, which group optionally contains one or more etheric oxygen atoms and optionally one or more carbon-carbon double or triple bonds, or c) a siloxane group, containing up to 50 silicon atoms, preferably in a linear chain.
- the alkyl or fluoroalkyl groups Q contains up to 24 carbon atoms, for instance up to 18 carbon atoms.
- Q is a straight or branched alkyl, alkoxyalkyl or oligoalkoxyalkyl chain containing 1-24 carbon atoms, unsubstituted or substituted by one or more fluorine atoms and optionally containing one or more carbon-carbon double or triple bonds or is a siloxane group as defined above.
- Q is: an alkyl group of formula -(CR 17 2 ) m CR 17 3/ wherein the groups -(CR17 2 )- are the same or different, and in each group -(CR 17 2 )- the groups R 17 are the same or different and each group R 17 is hydrogen, fluorine or C,- 4 alkyl or fluoroalkyl and m is from 5 to 23 if Q contains no fluorine atoms or from 1 to 23, preferably 5 to 23, if contains one or more fluorine atoms; an alkoxyalkyl having 1 to 12 carbon atoms in each alkyl moiety; unsubstituted or substituted by one or more fluorine atoms; or an (oligo-alkoxyl) alkyl group of formula -[ (CR 18 2 ) n O] 0 (CR 18 2 ) n R 18 where the groups -(CR 18 2 )- are the same or different and in each group -(CR 18 2 )- the groups R
- each group -(CR 16a 2 )- may be the same or different, preferably the same, and preferably each group R 1Sa is hydrogen.
- qq is from 2 to 4 , and is most preferably 3.
- Each group -(SiR 16b 2 )- may be the same or different, preferably the same, and preferably each group R ;DD is methyl.
- pp is from 4 to 29.
- the group Q does not contain any ethylenic unsaturation, i.e. any carbon-carbon double or triple bonds.
- comonomers containing an alkyl, fluoroalkyl or siloxane group include: methylmethacrylate, butylmethacrylate, n-dodecyl ethacrylate, octadecyl ethacrylate, hexadecyl methacrylate, 1H,1H,2H,2H- heptadecafluorodecyl methacrylate, p-octyl styrene, p- dodecyl styrene and monomethacryloxypropyl terminated siloxanes especially poly (dimethyl siloxanes) .
- n-Dodecyl methacrylate is particularly preferred.
- the groups R°, R 19 , R and R 14 represent the same meaning. preferably methyl.
- the groups A 1 , A 2 , A and A 4 represent the same group, and are preferably, -0-. Where such common features are present in the monomers, it is believed that copolymerisation proceeds in an optimum fashion, since the monomers are likely to have similar reactivity ratios.
- the polymers are made from their constituent monomers by radical polymerisation, typically using thermal, redox or photochemical initiation.
- the polymerisation conditions could be such that reaction between the silyl group of monomer of the formula II with the hydroxyl group of the monomer of the formula I does not take place to any significant extent during polymerisation.
- thermal polymerisation a temperature from 40 to 100°C, typically 50 to 80°C is used.
- actinic radiation such as gamma, U.V. , visible, or microwave radiation may be used.
- U.V. radiation of wavelength 200 to 400 nm is used.
- the polymerisation is generally performed in a reaction medium, which is for instance a solution or dispersion of the monomers in a liquid phase using as a solvent for example acetonitrile, dimethyl formamide, chloroform, dichloromethane, ethyl acetate, dimethyl sulphoxide, dioxan, benzene, toluene, tetrahydrofuran, or where the polymer does not contain groups which react with protic solvents, water or an alkanol containing from 1 to 4 carbon atoms, e.g. methanol, ethanol or propan-2-ol. Alternatively, a mixture of any of the above solvents may be used.
- a solvent for example acetonitrile, dimethyl formamide, chloroform, dichloromethane, ethyl acetate, dimethyl sulphoxide, dioxan, benzene, toluene, tetrahydrofuran, or where the polymer does not contain
- the polymerisation may be carried out in the presence of one or more polymerisation initiators, usually free radical generators, usually peroxides or azo initiators, such as benzoyl peroxide, 2 , 2 ' -azo-bis (2- methylpropionitrile) or benzoin methyl ether.
- polymerisation initiators which may be used are disclosed in "Polymer Handbook", 3rd edition, Ed. J. Brandrup and E.H. Immergut, Pub. Wiley-Interscience, New York, 1989.
- the polymerisation is performed for 1 to 72 hours, preferably 8 to 48, for instance 16 to 24 hours, and under an inert atmosphere of for example nitrogen or argon.
- the polymer is generally purified by dialysis, precipitation in a non-solvent (e.g. diethyl ether or acetone) or ultrafiltration.
- the resulting polymer is generally dried under vacuum, eg. for 5 to 72 hours and has a molecular weight from 10,000 to 10 million, preferably from 20,000 to l million.
- the monomer of the formula I it is preferable for the monomer of the formula I to be present in a molar excess to the monomer of the formula II.
- the two monomers are generally provided in the polymer in amounts so as to give the desired level of crosslinking when the polymer is used.
- the molar ratio of the monomer of the formula I to the monomer of the formula II is in the range 1:2 to 10:1, preferably 1:1 to 10:1, most preferably 2:1 to 6:1.
- a zwitterionic monomer of the formula III is included, it is generally contained in a molar quantity in the range 0.01%, preferably at least 1%, most preferably at least 5%, for instance at least 10%.
- the total amount is preferably less than 50%, for instance in the range 15 to 33%.
- comonomer of the formula V may be present in an amount in the range .01 to 99% by mole, most preferably in an amount in the range 1 to 95%, most preferably in the range 10 to 90%, for instance in the range 25 to 80%.
- the amount of monomer of the formula II is generally at least 1%, preferably at least 2%, for instance in the range 3 to 10%.
- the amount of monomer of the formula I is generally higher than the molar amount of monomer of the formula II, since this tends to encourage complete reaction of the trialkoxy silyl group of the monomer of the formula II.
- the residual, uncrosslinked hydroxyl group of the monomer of formula I is not very reactive, so that its presence in the crosslinked product does not cause problems with reactive interactions with fluids or solid substrates with which it is in contact.
- the crosslinkable polymer is of particular utility for coating applications.
- the present invention provides further coating compositions containing the crosslinkable polymer.
- Such compositions generally comprise a liquid vehicle within which the polymer is dissolved or dispersed.
- the liquid vehicle includes a solvent for the polymer in which the polymer is dissolved.
- the solvent may be an aqueous based solvent, but is more likely to be an organic solvent, for instance an alcohol or ether solvent.
- Coating compositions may comprise other components which assist wetting of an underlying surface and/or coating integrity.
- the present invention provides also processes in which substrates are coated with a liquid coating composition according to the invention, followed by a step in which solvent is removed from the coating, for instance by evaporation, and in which the polymer is, after coating, subjected to a crosslinking step in which it is subjected to conditions in which crosslinking takes place between the hydroxyl groups of the monomer of the formula I and one of the said OR lb groups of monomer of the formula II.
- Such reaction conditions generally involve subjecting the polymer to raise temperature, for instance under reduced pressure to remove alcohol R lb 0H by-product.
- a coating composition comprises monomers and, if necessary, a solvent for the monomers, and is subjected to conditions whereby reaction between the trialkoxysilyl group of monomer II and the hydroxyl group of monomer I takes place simultaneously with radical initiated polymerisation.
- the use of monomers of the formula I in combination with the formula II gives very good crosslinking levels, whilst producing a polymer product which has good integrity, that is cohesion, but adequate flexibility. It therefore provides a good coating for use on compliant substrates, especially substrates which are subjected to lengthening or other dimensional change in use.
- the substrate which is coated may be the metal of a stent or other biomedical device which is expanded in use.
- the substrate may be an elastomer, or a plastically expandable plastics material.
- Moulds were prepared by laminating glass sheets with polyethylene terephthalate (PET) film using spray mount. The moulds were assembled using a PTFE spacer. The monomer solutions were injected into the moulds and allowed to polymerise at 50C for 16 hours. Observations:
- This example illustrates a process in which the polymers are preformed and then coated.
- the polymerisation uses free radical solution polymerisation techniques following the standard method outlined below.
- a triple-necked round bottom flask 250ml was equipped with a Davis condenser, a nitrogen inlet, the, polymerisation solvent which is ethanol and a thermometer.
- the condenser was topped with a calcium chloride guard tube, and a magnetic follower was added to the flask.
- the reaction system then purged using nitrogen gas.
- the zwitterionic monomer was weighed and then stirred in the reaction solvent until dissolved.
- the comonomers were weighed and then stirred into the reaction solvent until dissolved.
- the initiator used throughout the polymer development was AIBN at a level of 2 w/w %, and this was dissolved into the reaction solvent.
- the solutions were then filtered under vacuum using a buchner funnel, into the reaction vessel.
- the solution was degassed using a constant flow of nitrogen for a period of twenty minutes, after which time the nitrogen flow rate was reduced and the temperature increased to 62C.
- the polymerisation was carried out under an atmosphere of nitrogen, and maintained at 62C for
- the polymer was then cooled using liquid nitrogen and ground to a fine powder using an analytical mill. The polymer was then further dried in vacuo at 25C for 16 hours. The yield of polymer obtained was recorded. Ethanol was the reaction solvent.
- Mv Viscosity Average Molecular Weight and is expressed in Daltons.
- the polymer was coated using dip coating from ethanol at 5 and 10 mg/ml. The coating speed was 3mm/min. The polymer was cross-linked by heating at 70C for 4 hours or longer eg overnight.
- the polymer was then used to coat a number of steel coronary devices crosslinked by heating and submitted to a number of tests which looked at the performance of the hydrogel coating during in vitro testing.
- Molecular weights for the polymer was found to be in the region of 200,000 daltons, with a radius of gyration of 14 nm.
- the biological performance (fibrinogen adsorption) of the novel polymers has been shown to be comparable to that of phosphorylcholine group containing copolymers currently used by Biocompatibles.
- the adsorption value was about 0.2 (comparative unit relating to absorbance in an ELISA test) for both PC polymers and about 1.8 for the uncoated steel.
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Macromonomer-Based Addition Polymer (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53065998A JP2001508480A (en) | 1997-01-10 | 1998-01-12 | Polymer |
US09/341,476 US6673883B1 (en) | 1997-01-10 | 1998-01-12 | Polymers containing zwitterionic monomers |
EP98900566A EP0953001A1 (en) | 1997-01-10 | 1998-01-12 | Polymers |
AU55666/98A AU5566698A (en) | 1997-01-10 | 1998-01-12 | Polymers |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9700390.9 | 1997-01-10 | ||
GBGB9700390.9A GB9700390D0 (en) | 1997-01-10 | 1997-01-10 | Device for use in the eye |
GB9718909.6 | 1997-09-05 | ||
GBGB9718909.6A GB9718909D0 (en) | 1997-09-05 | 1997-09-05 | Polymers |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998030615A1 true WO1998030615A1 (en) | 1998-07-16 |
Family
ID=26310770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/000070 WO1998030615A1 (en) | 1997-01-10 | 1998-01-12 | Polymers |
Country Status (5)
Country | Link |
---|---|
US (1) | US6673883B1 (en) |
EP (1) | EP0953001A1 (en) |
JP (1) | JP2001508480A (en) |
AU (1) | AU5566698A (en) |
WO (1) | WO1998030615A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000109A1 (en) * | 1999-06-24 | 2001-01-04 | Biocompatibles Limited | Balloon expandable stent |
WO2001001957A1 (en) * | 1999-05-27 | 2001-01-11 | Biocompatibles Limited | Local drug delivery |
WO2001005331A1 (en) | 1999-07-16 | 2001-01-25 | Biocompatibles Ltd | Braided stent |
WO2001089720A1 (en) * | 2000-11-02 | 2001-11-29 | Corus Staal Bv | Solution polymerized vinyl resin for primer applications |
WO2003025039A2 (en) * | 2001-07-09 | 2003-03-27 | Carlsberg A/S | Beaded polyethylene glycol-based resins |
US6852816B2 (en) | 2000-10-06 | 2005-02-08 | Biocompatibles Uk Limited | Zwitterionic polymers |
FR2876108A1 (en) * | 2004-10-05 | 2006-04-07 | Lafarge Sa | SUPERPLASTIFIERS WITH SILANE FUNCTIONS |
WO2008006912A2 (en) | 2006-07-14 | 2008-01-17 | Biocompatibles Uk Limited | Polymer |
WO2008006911A1 (en) * | 2006-07-14 | 2008-01-17 | Biocompatibles Uk Limited | Coated implant |
US7691839B2 (en) | 2005-09-28 | 2010-04-06 | Biovascular, Inc. | Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation |
US8057814B2 (en) | 2001-01-11 | 2011-11-15 | Abbott Laboratories | Drug delivery from stents |
US8372399B2 (en) | 2006-08-31 | 2013-02-12 | Cardiac Pacemakers, Inc. | Bispecific antibodies and agents to enhance stem cell homing |
US8512733B2 (en) | 2001-01-11 | 2013-08-20 | Abbott Laboratories | Stents with drug-containing amphiphilic polymer coating |
US8636995B2 (en) | 2006-08-31 | 2014-01-28 | Cardiac Pacemakers, Inc. | Methods and devices to regulate stem cell homing |
US9809717B2 (en) | 2010-05-25 | 2017-11-07 | 3M Innovative Properties Company | Antimicrobial-coated medical articles |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6743878B2 (en) * | 1991-07-05 | 2004-06-01 | Biocompatibles Uk Limited | Polymeric surface coatings |
GB9522332D0 (en) | 1995-11-01 | 1996-01-03 | Biocompatibles Ltd | Braided stent |
US7018401B1 (en) | 1999-02-01 | 2006-03-28 | Board Of Regents, The University Of Texas System | Woven intravascular devices and methods for making the same and apparatus for delivery of the same |
CN100594878C (en) * | 2004-03-31 | 2010-03-24 | 信越化学工业株式会社 | Cosmetic containing siloxane polymer |
US20110034396A1 (en) * | 2005-09-28 | 2011-02-10 | Biovascular, Inc. | Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions |
US20070129690A1 (en) | 2005-12-02 | 2007-06-07 | Joel Rosenblatt | Catheter with polymeric coating |
CA2667322C (en) | 2006-10-22 | 2016-09-13 | Idev Technologies, Inc. | Devices and methods for stent advancement |
CN103767810B (en) | 2006-10-22 | 2016-06-15 | Idev科技公司 | From the manufacturing process of extendable bracket |
US8423076B2 (en) * | 2008-02-01 | 2013-04-16 | Lg Electronics Inc. | User interface for a mobile device |
WO2010039828A1 (en) * | 2008-10-01 | 2010-04-08 | Teleflex Medical Incorporated | Article containing segregated biguanide and lewis acid |
US9023095B2 (en) | 2010-05-27 | 2015-05-05 | Idev Technologies, Inc. | Stent delivery system with pusher assembly |
US8900205B2 (en) | 2012-01-31 | 2014-12-02 | Terumo Kabushiki Kaisha | Syringe for prefilled syringe |
WO2013115331A1 (en) * | 2012-01-31 | 2013-08-08 | テルモ株式会社 | Syringe for use as pre-filled syringe |
JP6297992B2 (en) * | 2015-02-05 | 2018-03-20 | 信越化学工業株式会社 | Silicon-containing polymer, silicon-containing compound, resist underlayer film forming composition, and pattern forming method |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1549939A (en) * | 1967-01-05 | 1968-12-13 | ||
US4213886A (en) * | 1978-10-30 | 1980-07-22 | E. I. Du Pont De Nemours And Company | Treatment of aluminum flake to improve appearance of coating compositions |
EP0075957A2 (en) * | 1981-09-30 | 1983-04-06 | Union Carbide Corporation | Curable molding compositions containing a poly(acrylate) |
EP0412385A1 (en) * | 1989-07-31 | 1991-02-13 | Ppg Industries, Inc. | Aqueous compositions based on acid-functional acrylic silanol polymers |
JPH0539375A (en) * | 1991-08-05 | 1993-02-19 | Chisso Corp | Agricultural film |
JPH05271608A (en) * | 1992-03-24 | 1993-10-19 | Kansai Paint Co Ltd | Coating composition |
JPH05331251A (en) * | 1992-06-03 | 1993-12-14 | Kansai Paint Co Ltd | Curable composition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5302669A (en) * | 1985-09-09 | 1994-04-12 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Curable resin and process for preparing the same |
US4945145A (en) * | 1989-04-06 | 1990-07-31 | E. I. Du Pont De Nemours And Company | Silane coating composition for ambient cure |
US5162420A (en) | 1989-07-31 | 1992-11-10 | Ppg Industries, Inc. | Aqueous compositions based on acid-functional acrylic silanol polymers |
EP0593561B1 (en) | 1991-07-05 | 2000-03-22 | Biocompatibles Limited | Polymeric surface coatings |
JPH0751355A (en) | 1993-08-11 | 1995-02-28 | Kuraray Co Ltd | Medical synthetic high polymer and medical material |
GB9522332D0 (en) | 1995-11-01 | 1996-01-03 | Biocompatibles Ltd | Braided stent |
CA2192520A1 (en) * | 1996-03-05 | 1997-09-05 | Ian M. Penn | Expandable stent and method for delivery of same |
-
1998
- 1998-01-12 AU AU55666/98A patent/AU5566698A/en not_active Abandoned
- 1998-01-12 EP EP98900566A patent/EP0953001A1/en not_active Withdrawn
- 1998-01-12 JP JP53065998A patent/JP2001508480A/en active Pending
- 1998-01-12 US US09/341,476 patent/US6673883B1/en not_active Expired - Lifetime
- 1998-01-12 WO PCT/GB1998/000070 patent/WO1998030615A1/en not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1549939A (en) * | 1967-01-05 | 1968-12-13 | ||
US4213886A (en) * | 1978-10-30 | 1980-07-22 | E. I. Du Pont De Nemours And Company | Treatment of aluminum flake to improve appearance of coating compositions |
EP0075957A2 (en) * | 1981-09-30 | 1983-04-06 | Union Carbide Corporation | Curable molding compositions containing a poly(acrylate) |
EP0412385A1 (en) * | 1989-07-31 | 1991-02-13 | Ppg Industries, Inc. | Aqueous compositions based on acid-functional acrylic silanol polymers |
JPH0539375A (en) * | 1991-08-05 | 1993-02-19 | Chisso Corp | Agricultural film |
JPH05271608A (en) * | 1992-03-24 | 1993-10-19 | Kansai Paint Co Ltd | Coating composition |
JPH05331251A (en) * | 1992-06-03 | 1993-12-14 | Kansai Paint Co Ltd | Curable composition |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Section Ch Week 9312, Derwent World Patents Index; Class A14, AN 93-096841, XP002060536 * |
DATABASE WPI Section Ch Week 9346, Derwent World Patents Index; Class A18, AN 93-365463, XP002060535 * |
DATABASE WPI Section Ch Week 9403, Derwent World Patents Index; Class A14, AN 94-022958, XP002060534 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003503157A (en) * | 1999-05-27 | 2003-01-28 | バイオコンパテイブルズ・リミテツド | Local drug delivery |
WO2001001957A1 (en) * | 1999-05-27 | 2001-01-11 | Biocompatibles Limited | Local drug delivery |
US7754272B2 (en) | 1999-05-27 | 2010-07-13 | Biocompatibles IK Limited | Local drug delivery |
US6872225B1 (en) | 1999-05-27 | 2005-03-29 | Biocompatibles Uk Limited | Local drug delivery |
US8052746B2 (en) | 1999-06-24 | 2011-11-08 | Biocompatibles Limited | Balloon expandable stent |
WO2001000109A1 (en) * | 1999-06-24 | 2001-01-04 | Biocompatibles Limited | Balloon expandable stent |
US7794775B2 (en) | 1999-06-24 | 2010-09-14 | Biocompatibles Limited | Balloon expandable stent |
US7306625B1 (en) | 1999-06-24 | 2007-12-11 | Abbott Laboratories | Balloon expandable stent |
WO2001005331A1 (en) | 1999-07-16 | 2001-01-25 | Biocompatibles Ltd | Braided stent |
US7300990B2 (en) | 2000-10-06 | 2007-11-27 | Biocompatibles Uk Limited | Zwitterionic polymers |
US6852816B2 (en) | 2000-10-06 | 2005-02-08 | Biocompatibles Uk Limited | Zwitterionic polymers |
WO2001089720A1 (en) * | 2000-11-02 | 2001-11-29 | Corus Staal Bv | Solution polymerized vinyl resin for primer applications |
US8512750B2 (en) | 2001-01-11 | 2013-08-20 | Abbott Laboratories | Stents with drug-containing amphiphilic polymer coating |
US8512733B2 (en) | 2001-01-11 | 2013-08-20 | Abbott Laboratories | Stents with drug-containing amphiphilic polymer coating |
US8465758B2 (en) | 2001-01-11 | 2013-06-18 | Abbott Laboratories | Drug delivery from stents |
US8057814B2 (en) | 2001-01-11 | 2011-11-15 | Abbott Laboratories | Drug delivery from stents |
WO2003025039A2 (en) * | 2001-07-09 | 2003-03-27 | Carlsberg A/S | Beaded polyethylene glycol-based resins |
WO2003025039A3 (en) * | 2001-07-09 | 2003-10-23 | Carlsberg As | Beaded polyethylene glycol-based resins |
WO2006037888A1 (en) * | 2004-10-05 | 2006-04-13 | Lafarge | Silane-functionalized superplasticizers |
FR2876108A1 (en) * | 2004-10-05 | 2006-04-07 | Lafarge Sa | SUPERPLASTIFIERS WITH SILANE FUNCTIONS |
US7691839B2 (en) | 2005-09-28 | 2010-04-06 | Biovascular, Inc. | Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation |
US8188034B2 (en) | 2005-09-28 | 2012-05-29 | Biovascular, Inc. | Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation |
WO2008006911A1 (en) * | 2006-07-14 | 2008-01-17 | Biocompatibles Uk Limited | Coated implant |
WO2008006912A2 (en) | 2006-07-14 | 2008-01-17 | Biocompatibles Uk Limited | Polymer |
US8372399B2 (en) | 2006-08-31 | 2013-02-12 | Cardiac Pacemakers, Inc. | Bispecific antibodies and agents to enhance stem cell homing |
US8636995B2 (en) | 2006-08-31 | 2014-01-28 | Cardiac Pacemakers, Inc. | Methods and devices to regulate stem cell homing |
US9809717B2 (en) | 2010-05-25 | 2017-11-07 | 3M Innovative Properties Company | Antimicrobial-coated medical articles |
Also Published As
Publication number | Publication date |
---|---|
JP2001508480A (en) | 2001-06-26 |
EP0953001A1 (en) | 1999-11-03 |
US6673883B1 (en) | 2004-01-06 |
AU5566698A (en) | 1998-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6673883B1 (en) | Polymers containing zwitterionic monomers | |
US7160953B2 (en) | Polymeric surface coatings | |
EP0593561B1 (en) | Polymeric surface coatings | |
Xu et al. | pH-and temperature-responsive hydrogels from crosslinked triblock copolymers prepared via consecutive atom transfer radical polymerizations | |
EP0714417B1 (en) | Polymer surface coatings | |
KR100313132B1 (en) | Perfluoropolyether paint with acryl group | |
US20040063881A1 (en) | Zwitterionic polymers | |
US4713441A (en) | Polyacetal hydrogels formed from divinyl ethers and polyols | |
US4985559A (en) | UV Absorbing vinyl monomers | |
EP0193370A2 (en) | Fluorinated polyacrylates and polyacrylamides having a controlled cross-linking degree, and process for preparing same | |
AU2012273774A1 (en) | Biocompatible, biomimetic ampholyte materials | |
EP0121918A1 (en) | Novel fluorine-containing vinyl compounds | |
JP2003511538A (en) | Zwitterionic polymer blend materials | |
EP0930357A1 (en) | Contact lens cleaning solutions | |
EP0818479B1 (en) | Polymeric surface coatings | |
US3893988A (en) | Copolymers of alkoxy and hydroxy alkyl methacrylates and a process for their preparation | |
Kim et al. | Synthesis of urethane graft copolymers with perfluoroalkyl and silicone‐containing side chains and their surface properties | |
Oishi et al. | Synthesis and properties of poly (methacrylate) bearing a phosphorylcholine analogous group | |
EP1189956B1 (en) | Polymer solutions | |
JP3484591B2 (en) | Plastic molded article, method for producing the same, and optical article | |
Hyder Ali et al. | Synthesis and characterization of cinnamoyloxyethyl (meth) acrylates and their copolymeric hydrogels | |
Lu et al. | Synthesis and polymerization of γ‐alkoxy‐β‐hydroxypropyl acrylates | |
JP7401876B2 (en) | Fluoropolymers, membranes and medical devices | |
JPH04120114A (en) | Production of fluorine-containing block copolymer and coating material containing the same | |
KR20060070540A (en) | Etherified carbamate functional copolymers of isobutylene type monomers, and their use in curable compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998900566 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 530659 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09341476 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998900566 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998900566 Country of ref document: EP |